Bli medlem
Bli medlem

Du är här


DBP International AB: Mexico patent for Temodex / SI-053 is granted


Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, June 28th 2021, received information about the granting of Mexican patent application concerning the company's front-line product Temodex / SI-053.
Patent approval provides protection for the technology and the product in Mexico until at least 2036.
"This is a very important milestone in the development of SI-053 as Mexico is a fast growing market where we plan to expand the global commercialization of the product," comments Igor Lokot, CEO of DBP. - "We also have other applications pending for other important markets."
More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally. Video presentation: 

This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-06-2021 08:40 CET.

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.